Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.49 |
| ▸ | CKS1B | P61024 | 1/20 | 0.49 |
| ▸ | SKP1 | P63208 | 1/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658656 | 0.86 | LRRK2 (0.50) | SSTR4CKS1BSKP1SKP2IRAK4 | |
| SCHEMBL19652157 | 0.83 | CKS1B (0.52) | SSTR4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL19652097 | 0.81 | MEN1 (0.55) | SSTR4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL19652195 | 0.79 | PANK3 (0.48) | SSTR4CKS1BSKP1SKP2ALDH1A1 | |
| SCHEMBL24962329 | 0.78 | HRH4 (0.44) | CHRM5CHRM1CHRM3CHRM4TP53 | |
| SCHEMBL19652135 | 0.77 | AAK1 (0.39) | CHRM5CHRM1CHRM3CHRM4TP53 | |
| SCHEMBL17753020 | 0.75 | IDH1 (0.39) | IRAK4CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL3870833 | 0.73 | JAK2 (0.43) | ALDH1A1LMNACHRM5CHRM1CHRM3 | |
| SCHEMBL23073749 | 0.73 | AR (0.46) | ALDH1A1LMNACHRM5CHRM1CHRM3 | |
| SCHEMBL23744455 | 0.73 | CHRM3 (0.61) | CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | SSTR4 3546/4885CKS1B 239/4885SKP1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.